tirzepatide covered by cigna FDA Grants a New Indication for Obesity Management Tirzepatide Weight Loss Injections &

For example: A meta-analysis of 76 randomized trials found that use of GLP-1 receptor agonists (the drug class Ozempic belongs to) raises the risk of gallbladder and biliary diseasesespecially at higher doses or over longer durationswith relative risks ranging from 1.27 to 1.55 depending on the condition

Make sure youre drinking enough fluids every day

Keep a record of any skin changes and show your provider photos if reactions recur

However, to impact macro-vascular disease, the drug chosen to lower blood glucose concentration may be more important [6]

Recent pharmaceutical interventions, especially GLP-1RAs, have advanced treatment for glycemic control and obesity